EMA
- Application: EMEA/H/C/005927
- Marketing authorisation holder: Pharming Technologies B.V.
- Local brand name: Joenja
- Indication: Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)
- Pathway: orphan
- Status: approved
🇪🇺 Joenja in European Union
Joenja (LENIOLISIB) regulatory status in European Union.
Marketing authorisation
Joenja in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in European Union
Frequently asked questions
Is Joenja approved in European Union?
Yes. EMA has authorised it.
Who is the marketing authorisation holder for Joenja in European Union?
Pharming Technologies B.V. holds the EU marketing authorisation.